Earnings Preview: Akamai, Advanced Micro Devices, Gilead Sciences, Biogen, Celgene Seeking Alpha Tysabri sales over $280 million would be a positive indicator, but the key question is data or FDA approvals for late-pipeline drugs like BG-12 or Daclizumab for multiple sclerosis, which are likely to be announced on other occasions. ... |
